SK Biopharmaceuticals Co., Ltd.
326030
Clasificación en acciones
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Precio por acción
$51.65
Capitalización bursátil
$4.05B
Cambio (1 día)
0.27%
Cambio (1 año)
-30.95%
País
KR
Comercio SK Biopharmaceuticals Co., Ltd. (326030)
Categoría
Healthcare
Ganancias de SK Biopharmaceuticals Co., Ltd. (326030)
Ganancias en Jun 2026 TTM: $199.99M
Secondo gli ultimi rapporti finanziari di SK Biopharmaceuticals Co., Ltd., gli utili attuali della società sono $199.99M. Nel 2024, la società ha registrato un utile di $49.38M, un aumento con respecto a agli utili del 2023, che erano di $-33.88M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de SK Biopharmaceuticals Co., Ltd. desde 2011 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $199.99M | 91.48% |
| 2025 | $104.44M | 111.52% |
| 2024 | $49.38M | -245.75% |
| 2023 | $-33.88M | -69.99% |
| 2022 | $-112.90M | -288.31% |
| 2021 | $59.95M | -127.13% |
| 2020 | $-220.98M | 202.16% |
| 2019 | $-73.13M | -40.83% |
| 2018 | $-123.61M | 36.08% |
| 2017 | $-90.84M | 260.75% |
| 2016 | $-25.18M | 14.75% |
| 2015 | $-21.94M | -33.74% |
| 2014 | $-33.12M | -18.07% |
| 2013 | $-40.42M | 43.63% |
| 2012 | $-28.14M | 57.64% |
| 2011 | $-17.85M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 2,537.63% |
US
|
|
| $-3.09B | -1,643.61% |
US
|
|
| $-4.02B | -2,108.24% |
AU
|
|
| $1.95B | 875.39% |
NL
|
|
| - | - |
CH
|
